SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Pueblo who wrote (115373)10/18/2000 12:50:12 AM
From: Jenna  Read Replies (1) of 120523
 
RX.. earnings out today. combination of great fundamentals and excellent chart (do your own DD)

IMS HEALTH (RX) Reports COX-2 Drug Sales In U.S. Surge 137 Percent In Six-Month Period
IMS HEALTH (NYSE:RX - news) reported today that COX-2 inhibitors, a class of drugs introduced in 1999 for treating the pain of arthritis and other acute pain, posted 137 percent growth in U.S. sales for the six months ending in July. In the span of just 20 months, COX-2 drugs -- including Pharmacia's Celebrex and Merck's Vioxx -- have become the 11th-largest therapeutic class of drugs in the U.S., with sales of $3.0 billion and the volume of dispensed drugs topping 102 million for the 12-month period ending in July. IMS HEALTH is the world's leading provider of information solutions to the pharmaceutical and healthcare industries.
(See press release) (10/17/00)

Trend is strong and all indicators are showing RX is in a nice bullish uptrend. Not overbought and comfortably below its year high.

When
Analyst Action 13-Oct-00 CSFB initiated: at Buy
3-Oct-00

Lehman Brothers upgrade: from Outperform to Buy
29-Sep-00

29-Sep-00
FAC/Eqts First Albany initiated: at Strong Buy

24-Aug-00
Deutsche Bc Alex. Br initiated: at Strong Buy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext